Acute asthma remains an important medical emergency, the most frequent cause of acute admissions in children and a major source of morbidity for adults with asthma. In all ages with asthma, the presence of exacerbations is an important defining characteristic of asthma severity. In this review, we assess the epidemiology of acute asthma, the triggers of acute exacerbations, and the mechanisms that underlie these exacerbations. We also assess current treatments that prevent exacerbations, with an emphasis on the role of type 2 airway inflammation in the context of acute exacerbations and the novel treatments that effectively target this. Finally we review current management strategies of the exacerbations themselves.
Acute exacerbations of asthma remain a serious treatment challenge. They are a frequent cause of hospital admission or emergency room presentation, especially in children. According to the World Health Organization, asthma was responsible for 180,000 deaths in 2013 (1) . Exacerbations are now considered to be key in defining the severity of the disease, and their prevention is an important metric to measure the success of asthma treatments (2) . Definitions of acute asthma or exacerbations have varied over the years, and a more precise definition was required to standardize outcomes in clinical trials and clinical medicine. As a result, the American Thoracic Society/European Respiratory Society convened a task force to define exacerbations as well as asthma control (3) . Consequently, a severe exacerbation was defined as requiring the use of corticosteroids for at least 3 days or a hospitalization or emergency room visit because of asthma requiring corticosteroids. Moderate exacerbations were defined as an event that required a change in treatment to prevent it from becoming severe and not severe enough to warrant oral corticosteroids (OCS).
The interventions available for use in the setting of acute asthma are relatively limited, and the management of asthma exacerbations varies depending on severity and the treatment setting. Since the 1960s, treatment for acute asthma has focused on the use of systemic corticosteroids and selective b 2 -agonists. Unfortunately, since then, there have been few new treatments trialed and little added of particular efficacy in the armamentarium of acute management of asthma exacerbations, with the exception of supportive measures. The treatment of asthma exacerbation currently begins with asthma self-management in the outpatient setting. As the severity of the presentation escalates, so do treatment regimens and the support required. Here we review the mechanisms that underpin acute asthma and its management (Table 1) .
and females are more likely to suffer with acute asthma throughout life. In terms of seasonality, there is a peak of events when children return to school in autumn. Younger children and adults experience less pronounced increases after this time of the year, and a smaller peak also occurs in those more than 50 years of age in midwinter. Both of these peaks are associated with the presence of virus infections (4) .
These events seem to hold true across the developed world and are well illustrated by Australian data (5) . The problem is greatest in childhood, with children being hospitalized at a prevalence of 495 per 100,000, compared with adults at 92 per 100,000. Deaths from asthma, though, were rare in 2016, with only 455, and two-thirds of these were in those aged more than 75 years. These epidemiological data also demonstrate how much asthma is also a disease of the social environment. In Australia, despite universal public health care, the prevalence of acute asthma was higher in populations with a lower socioeconomic background and was twofold greater among indigenous communities and higher in adults living in remote areas (5) . Outcomes of studies of the relationships between asthma incidence and lower socioeconomic status (SES) have varied from no relationship (6) to increased risk (7) . In general, although asthma tends to be a disease of the developed world, explained in part through the hygiene hypothesis, when present, poverty is nearly always associated with worse outcomes (8) . Lower SES has consistently been shown to be an independent risk factor for poor asthma control and exacerbations (9, 10) , although differential effects have been seen based on ethnicity (11) . In developing nations, poverty or low SES is similarly associated with poor asthma outcomes (12) . The reasons for this are likely to be complex, including poor nutrition, access to health care, affordability of medicine, and exposure to cigarette smoke and/or pollution (8) . Although easy to dismiss as a problem to be solved by government and changes in social policy, well conducted, patient-centered interventions that focus on self-management can successfully deliver improved outcomes, including reducing exacerbations (13) .
Triggers for Acute Asthma
The seasonal variation in asthma exacerbations, especially in children, has already been described, particularly the marked increase that accompanies the return to school in autumn. This has been linked strongly with the presence of rhinovirus (RV) infection and lack of preventer use in Canadian children aged 5 to 15 years (14) . Less intense peaks have also been seen in midwinter in older adults and patients with chronic obstructive pulmonary (COPD) disease and associated with influenza (15) . Although other factors contribute to this seasonal variation in acute asthma, in school-age children, the community prevalence of RV is the strongest predictor (16) . Associations between respiratory infections and acute asthma have been recognized for centuries, as described in 1864 by Henry Salter (who had asthma himself), "the most prominent and frequent of all exciting causes is what is commonly called taking cold.. The asthma consequent on cold on the chest (bronchitis) is of a most painful and distressing kind; unlike that produced by Figure 1 . Acute exacerbations of asthma follow a pattern of seasonal variation. A number of seasonal peaks of acute asthma activity occur. There is a marked increase that accompanies the return to school in autumn. This has been linked strongly with the presence of rhinovirus (RV) infection and lack of preventer use in schoolchildren with asthma. A less intense peak has also been seen in midwinter in older adults and patients with chronic obstructive pulmonary disease and associated with influenza and other winter-related respiratory tract infections. Exposure to allergens, however, is also important. After adjusting for season and air pollution, a doubling in grass pollen levels and fungal spore counts is also associated with increased asthma admissions. This is associated with a third peak in late spring correlated with high grass pollen counts and high humidity, seen through a combination of high ambient pollen counts and weather events like thunderstorms.
cold directly, it often lasts for days" (17) . The ability to identify viruses by PCR demonstrated that they were associated with 80% to 85% of asthma exacerbations in children and the majority in adults (18) , with RV the most common. Although true to Salter's description, exacerbations associated with viral infections have also been shown to have increased severity (19) .
Recently it has been shown that certain RV strains are more closely linked to acute asthma. In children, the newly identified RV-C strains were detected in 59.4% and associated with more severe disease (19) . In childhood, RV-C strains seem particularly capable of causing exacerbations; infections with RV-A strains require a higher viral titer to trigger an exacerbation, whereas RV-B strains seem relatively benign (20) . RV-C strains bind to epithelial cells via the cadherin-related family member 3 protein, with a missense single nucleotide polymorphism (rs6967330, C529Y) linked to greater cell-surface expression (21) . This mutation has also been linked to childhood severe asthma exacerbations (22) , and, recently, this enhanced risk was found to be due to RV-C-associated exacerbations in two separate birth cohorts (23) . Although this strong association has been seen in children with acute asthma and RV-C, it does not seem to hold true for adults, in whom RV-A strains dominate and RV-C strains were rarely identified in Australian (24) and U.S. (25) cohorts.
Environmental factors influence asthma exacerbations. A Canadian study showed that after adjusting for season and air pollution, a doubling in grass pollen levels and fungal spore counts increased asthma admissions (26) . A U.S. study also showed a potential relationship between mold spore levels and asthma deaths (27) , whereas another study and a meta-analysis linked outdoor pollen exposure to acute asthma events (28, 29) . More recently, an Australian study demonstrated three separate peaks of asthma admissions, the first two related to virus infection but the third, in late spring, correlated with high grass pollen counts and high humidity, implicating thunderstorms as a trigger (30) . Acute thunderstorm asthma events are extreme examples of this phenomenon, where high pollen counts combine with atmospheric conditions that induce severe acute asthma epidemics (31, 32) , associated with intense type 2 airway inflammation (33) (Figure 1 ).
Exacerbation-Prone Asthma Phenotype
Within populations, the risk of asthma exacerbations is not equal. In children, a history of previous severe exacerbations appears to be the strongest predictor, along with poor asthma symptom control and disease severity (34) (35) (36) . This risk, though, appears to vary by season, with exacerbations occurring in autumn and winter (usually viral) predicted by a history of previous exacerbations and atopy and those in spring and summer by dose of inhaled corticosteroids (ICS) required for control (37) . This suggests that, at least for events associated with allergy in autumn, these may be better controlled by regular use of ICS.
In adults, analysis of three clinical trials of more than 7,000 subjects with asthma who had their treatment with ICS/longacting b-agonist (LABA) therapy optimized, exacerbations were predicted by disease severity, asthma symptom control, and a history of smoking (38) . The presence of eosinophilia and bronchodilator responsiveness has also been linked to exacerbation-prone asthma in one cohort (39) . Unlike in childhood, in adults, comorbid disease is also an important additional factor. This has been consistently seen with chronic rhinosinusitis, gastroesophageal reflux, body mass index, and psychological dysfunction (39) (40) (41) . In adults with severe asthma, the complexity of this situation needs to be appreciated if effective strategies are to be designed to prevent exacerbations. Using registry data, McDonald and colleagues demonstrated that 24 individual treatable traits could be identified in the domains of pulmonary, extrapulmonary, and behavioral factors that were overrepresented in those with severe asthma and were related to risk of exacerbation (42) . In the context of severe asthma, a single approach that only focuses on asthma disease control then is unlikely to be sufficient to improve patient outcomes.
Poor Asthma Control and Type 2 Airway Inflammation in Acute Asthma
The presence of refractory type 2 airway inflammation has emerged as a key independent risk factor for exacerbations, and this provides important insight into the pathophysiology of acute asthma. Type 2 inflammation is characterized by the release of the cytokines IL-5, IL-4, and IL-13 produced by T-helper type 2 (Th2) cells and innate lymphoid cells of type 2 and is associated with airway eosinophilia and elevated levels of exhaled nitric oxide.
Asthma severity and asthma symptom control independently predict exacerbation risk, as do sputum eosinophilia and elevated exhaled nitric oxide (43) . Although adultonset asthma is often not associated with atopy, a large number, especially those with more severe disease, have evidence of type 2 immune activation, with elevated sputum eosinophils and increased levels of exhaled nitric oxide (44) . More recently, blood eosinophils have been identified as a good predictor of airway eosinophils (45) . In population samples of adults, elevated blood eosinophils are associated with increased risk of exacerbations. In 2,392 subjects with asthma, a blood eosinophil count of greater than 0.4 3 10 9 /ml independently predicted exacerbation risk with an odds ratio of 1.31 (95% confidence interval, 1.07-1.6) (46). This remained an independent predictor for exacerbations, even in those with poor asthma symptom control (47) , and showed the strongest association with the most severe exacerbations that result in hospital admission (odds ratio, 5.14; 95% confidence interval, 1.76-14.99) (48). Combining elevated blood eosinophils together with exhaled nitric oxide may further define those at greatest risk of future asthma exacerbations (49) . The presence of active type 2 airway inflammation and its measurement with biomarkers such as blood eosinophils and exhaled nitric oxide provides a clear indication of risk for future exacerbations.
Non-Type 2 Airway Inflammation in Acute Asthma
Although the role of type 2 airway inflammation in acute asthma is becoming much clearer, other immune processes are likely to also be important, and future treatments will likely rely on a clearer understanding of these (50) . Acute exacerbations, especially those associated with virus infection, have been shown to be associated with neutrophilic inflammation (51) , although in the setting of eosinophilic cationic protein, which might suggest mixed inflammation. This may differ in children, where there is more evidence of eosinophilic inflammation (52) . Non-type 2 inflammation in asthma has been linked to dysregulation of innate immune responses, including the activation of inflammasome pathways and development of airway neutrophilia (53, 54) . In recent mechanistic and clinical studies, non-type 2 airway inflammatory mechanisms play a key role in exacerbations, with microRNAs and inflammasomes more likely to be involved in viral infection and contribute to corticosteroid-resistant processes (55, 56) .
Prevention and Management of Exacerbations Controlling Type 2 Airway Inflammation
Control of type 2 airway inflammation is critical in preventing exacerbations ( Table 2) . Treatment with ICS remains the cornerstone strategy for the majority with asthma and is effective in most at reducing the risk of exacerbations, including the risk of death (57) (58) (59) . Using either OCS or ICS, adjusted to suppress airway eosinophilia in asthma, has been shown to effectively reduce the risk of exacerbations (60, 61) . More recently, biologic treatments that target specific aspects of type 2 immune responses in those with severe asthma and ICS-refractory type 2 airway inflammation have been shown to reduce asthma exacerbations. Treatment of patients with severe allergic asthma with omalizumab, a monoclonal antibody to IgE, reduces exacerbations in those with severe disease despite optimal doses of ICS/LABA (62) . In subjects with severe asthma and refractory eosinophilia, Farne and colleagues demonstrated that monoclonal antibody therapy against IL-5 and the IL-5 receptor reduced exacerbation frequency by approximately half (63) . Meanwhile, treatment with dupilumab, a monoclonal therapy against the shared receptor of IL-4 and IL-13, similarly reduced asthma exacerbations, although only in those with persistent type 2 airway inflammation, as measured by either increased blood eosinophils or exhaled nitric oxide, despite treatment with ICS (64, 65).
Self-Management
The Global Initiative for Asthma, along with most international respiratory societies, recommend self-management strategies to reduce the impact of acute exacerbations in all groups (2) . This involves patient education and the provision of an individualized written asthma action plan. An action plan should include a description of regular maintenance therapy and instructions for the escalation of therapy depending on either a worsening of symptoms or a change in peak flow (for examples, see https://www.nationalasthma. org.au/health-professionals/asthma-actionplans/asthma-action-plan-library). Action plans that include instructions using two to four action points and are coupled with the use of both ICS and instructions on when to initiate OCS improved health outcomes, including a reduction in hospital admissions (66) .
Bronchodilators
Since their advent, short-acting bronchodilators to relieve the symptoms of acute asthma have featured prominently. Both b 2 -agonists and short-acting antimuscarinics act on airway smooth muscle to promote bronchodilation. This is mediated by b-adrenergic stimulation of smooth muscle relaxation to enact bronchodilation or cholinergic antagonism to relieve bronchial constriction that is under parasympathetic activity (67, 68) . Their utility in relieving symptoms is clear and vital, but their potential to delay seeking help and their failure to address airway inflammation compromise their value and may increase the risk of adverse outcomes in acute asthma (69) .
Adjusting ICS/OCS
Control of type 2 airway inflammation prevents exacerbations but also improves outcomes during an exacerbation. Treatment with systemic steroids, including 1 to 6 days of prednisone or dexamethasone, effectively reduced relapse rates in acute asthma in children (70) . Similarly, in adults, systemic steroids reduced acute relapse rates, although the course of prednisone needed to be at least 5 to 10 days in duration, with shorter courses being ineffective (2, 71, 72) . Treatment with ICS cannot be used in place of OCS (73) but may prevent the need to use OCS in acute asthma. Quon and colleagues showed that doubling the maintenance dose of ICS at the start of an exacerbation was insufficient to prevent the use of OCS in adults (74) and is also the case in children (75) . In adults, Oborne and colleagues assessed whether quadrupling the dose of ICS could prevent exacerbations needing OCS (76) . Although they failed to reach their primary outcome, possibly because the required fall in peak flow to trigger their action plan provided a delayed response, those who actually did increase their ICS used less OCS. McKeever and colleagues have demonstrated, in a larger pragmatic trial of 1,922 subjects, a longer time to first exacerbation in the group of subjects instructed to quadruple their dose of ICS at the start of exacerbation (77) . Although this approach appears effective in adults, it is necessary to be aware of local side effects of increased ICS dose, which were elevated in the treatment group. Nevertheless, this side-effect profile is still likely to be less than seen with systemic oral corticosteroids.
A more flexible approach that adjusted ICS dose in response to symptoms has been shown to be more successful. Formoterol/budesonide combinations have shown utility in the setting of mild asthma exacerbations and loss of asthma control when used as maintenance and reliever therapy (78) . Formoterol has a rapid onset of action of 1 to 3 minutes and also a prolonged duration of action (79) and allows it to be used as reliever therapy. This has a role in the setting of mild asthma exacerbations, where, instead of typical short-acting bronchodilators, budesonide/formoterol combination inhalers lead to symptomatic bronchodilation along with the administration of extra ICS. Ideally, this extra ICS may be sufficient to target steroid-responsive inflammation that may be at the heart of the current exacerbation. As a result, adjustable dosing of budesonide/formoterol is linked with better exacerbation control long term (80) . More recently, this approach was used to show that as-required use of formoterol/budesonide, in those with mild intermittent disease, also effectively reduced exacerbations and the need for OCS (81, 82) .
Treatment in the setting of severe exacerbations currently involves therapy with OCS. Their use is associated with reduced recurrent asthma exacerbations and emergency department and hospital admissions (83) . Given that many exacerbations often involve eosinophilic inflammation beyond what is typically managed with maintenance therapy in the patient's day-to-day life, systemic corticosteroids effectively target this increased inflammation. They have been shown to induce apoptosis in eosinophils, reduce mucus hypersecretion in the airways, and prevent the recruitment of eosinophils. All of this contributes to their importance as a major therapy in the treatment of acute asthma exacerbations (84) .
Magnesium
The use of magnesium sulfate is limited to those situations where asthma exacerbation is refractory to treatment with bronchodilators and steroids alone. Parenteral administration is used, as it has greater bioavailability than oral magnesium (85) . A Cochrane review demonstrated reduced hospital admissions and a small improvement in lung function with the use of magnesium sulfate in the emergency department (86) . A review by Ling and Definition of abbreviations: ICS = inhaled corticosteroid; LABA = long acting b-agonist; PBMC = peripheral blood mononuclear cell; RCT = randomized controlled trial; TSLP = thymic stromal lymphopoietin.
colleagues did not demonstrate any reduction in hospital admissions with the use of nebulized magnesium, and thus there is no clear benefit to nebulized administration at this point (87) . Another Cochrane review assessed comparisons between the administration of inhaled magnesium sulfate and b 2 -agonist with b 2 -agonist alone. This also did not show any improvement in lung function or hospital admission rate (88) . These findings seem to be equivalent in children (89) . The options mentioned above for the management of exacerbations of asthma in the acute setting are summarized in Table 3 .
Treating Infection and Non-Type 2 Inflammation
Infection plays a crucial role in triggering acute asthma. Experimental studies show impaired innate immune responses to virus infections in asthma (90) and that infections induce microRNAs and inflammasome activation that suppress responses to corticosteroids (55, 56) . Investigators sought to determine if treatment at the time of a cold with nebulized IFN would reduce exacerbation severity in those with a history of virus-induced acute asthma. Treatment, though, did not improve the severity of acute asthma symptoms overall, except in those with preexisting poor control and more severe disease (91) . Lack of effect in this study may have also been due to a lack of change of symptoms in those with milder disease. In contrast to acute exacerbations of COPD, there is little evidence that antibiotics improve outcomes in acute asthma (92) , particularly not with respect to hospital admissions or exacerbations. This is likely because the majority of exacerbations are associated with viral infections. Macrolide antibiotics have been used to reduce the frequency of exacerbations of asthma and other airways disease and are proposed to have antiinflammatory effects. In a trial of 278 adults with asthma, treatment with the ketolide telithromycin was shown to improve asthma symptom scores (93) , but it was later withdrawn because of toxicity. A similar trial attempted to assess add-on azithromycin to see if this would improve asthma symptoms acutely. The trial failed to demonstrate a difference, although the investigators had to exclude 10 subjects for every one randomized, as they had already received antibiotics (94) . Azithromycin has also been used in preschool children (1-3 yr) presenting with acute wheezing illnesses but has had mixed results, with trials demonstrating a reduction in length of symptoms (95) and lower risk of more severe disease (96); a separate study failed to show improvement in clinical outcomes (97) . Antimicrobials, instead, should be reserved for those cases where there is clinical suspicion for bacterial infection that requires treatment (2) .
In terms of preventing exacerbations by targeting non-type 2 immune mechanisms, there have been mixed results ( Table 2 ). In adults with moderate to severe asthma, regular azithromycin reduced exacerbation risk in those with and without eosinophilic airway inflammation in an Australian study (98) but only in a noneosinophilic subgroup in a European study (99) . The latter, however, may not have had sufficient power to detect this effect in both phenotypes and also used a lower dose of azithromycin. Tiotropium, a long-acting anticholinergic bronchodilator, has also been shown to reduce exacerbation risk in those on ICS/LABA in adults and improve FEV 1 in both adults and adolescents with asthma (100). Omalizumab, as discussed earlier, reduces exacerbations, but recent evidence suggests part of its effect may also be by improving antiviral immune responses (101, 102) . A monoclonal antibody targeting Th17 was not able to improve Asthma Control Questionnaire scores in one 12-week study, although exacerbations were not considered as an endpoint (103) . Tumor necrosis factor-a (104) and a chemokine receptor (CXCR2) antagonist (105) have also failed to reduce exacerbations. Of note, a promising study has been recently completed that demonstrated the efficacy of tezepelumab, a monoclonal antibody against Summary of treatment modalities for asthma exacerbation. In the acute setting, the use of Class 1 medications for symptom relief is standard, in addition to Class 2 to target inflammation at the heart of an acute exacerbation and prevent relapse. Class 3 medications are typically used in refractory situations, or where there is clinical need for treatment of comorbidities or ongoing supportive management.
thymic stromal lymphopoietin, to reduce exacerbations in patients with moderate to severe asthma, regardless of type 2 inflammatory status (106) . Further studies will be needed to clarify its role in the management of asthma and, particularly, its utility in the non-type 2 group. In order for treatment of acute asthma to move forward, it is likely we will need to better understand the mechanisms behind exacerbations, and this may involve appreciating a greater heterogeneity in acute asthma. In a recent small trial of acute COPD and acute severe asthma, Ghebre and colleagues demonstrated three clusters on the basis of sputum/blood mediators, airway microbiome, and clinical characteristics (107) . Overall inflammatory mediators increased acutely, but there were three distinct clusters: 1) neutrophilic/IL-b dominant associated with pathogenic bacteria, 2) eosinophilic/type 2 immune dominant and type 1 immune active (possibly virus induced), and 3) high IFN-g serum CXCL-10 (107). This points to a previously unrecognized heterogeneity with exacerbations. A one-size-fits-all approach for acute asthma using systemic corticosteroids and bronchodilators then is likely to only take us so far. Approaches that target preexisting inflammation and susceptibility have proven successful in preventing exacerbation, but to treat the acute event we may need now to identify and target the acute pathology more precisely. The use of antibiotics, including macrolides, may have greater impact in exacerbations associated with neutrophilia and bacterial infection. Repurposing failed treatments against Th-17 or CXCR2 in an acute context with neutrophilic inflammation or nebulized IFN-b with virus infection may need to be considered with intervention trials designed to improve acute outcomes. Similarly, investigating the role of mucus hypersecretion and small airway obstruction and therapies targeting this in acute asthma has been long neglected (108) and would be a novel direction to take new treatment strategies.
Conclusions
The treatment of asthma exacerbations using the therapies described is successful for a large proportion of patients. Indeed, as a result, over the course of the last 100 years, the mortality rate from asthma exacerbations has declined considerably. This has largely been due to the recognition of corticosteroids as a cornerstone in the prevention and acute treatment of asthma exacerbations. Despite these improvements, however, there remains a significant ongoing mortality rate due to asthma that appears to have reached a plateau in the developed world (109) . With the advent of precision medicine and targeted therapies, there have been many new insights into the management of asthma as a chronic disease, including the prevention of exacerbations; however, this has not yet been seen with respect to the management of exacerbations in the acute setting. We remain hopeful that further advances in this field will lead to a further decline in the mortality ratewhether this be due to advances in chronic therapy, the acute management of exacerbations, or even, potentially, the development of a cure for asthma. n
